Medicenna Therapeutics Corp's stock increased by 3.61% in the last trading session, showing positive investor sentiment.
On the TSX, Medicenna Therapeutics Corp (MDNA.TO) closed at CA$0.43. This rise comes as the company makes strides in its funding strategies and market positioning, attracting investors interested in promising biotech opportunities.
Advertisement
Get up to $2,000 cash back
Open and fund a new Qtrade account with promo code SPRING26. Offer ends July 31, 2026.
Medicenna Therapeutics Corp
MDNA.TO
MDNA.TO
Medicenna Therapeutics Corp
WealthAwesomeMarket cap
$33.69M
52W high
$1.97
52W low
$0.36
1W change
-6.41%
Beta
1.89
Analyst Price Targets
Based on analyst covering MDNA
Wall Street analysts forecast MDNA stock price to rise 776.7% over the next 12 months.
Consensus
BullishBased on avg. target vs last close (formal rating unavailable for Canadian listings)
Avg. Target
C$3.20
+776.7% Upside
Current Price
C$0.36
Last close
Analyst ratings and price targets are updated periodically. Not financial advice.
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on MDNA's historical volatility
30-Day Vol
44.4%
Annualized
90-Day Vol
70.3%
Annualized
Trend (90d)
-50.0%
Annualized drift
90d Mean
C$0.31
Expected price
| Horizon | Expected | 68% Range (1σ) |
|---|---|---|
| 30 trading days | C$0.34 | C$0.30 – C$0.40 |
| 60 trading days | C$0.32 | C$0.26 – C$0.40 |
| 90 trading days | C$0.31 | C$0.23 – C$0.40 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ±1σ, 95% band = ±2σ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
Investor takeaway: The uptick in Medicenna's stock price indicates growing confidence among investors, especially after the company's recent public offerings aimed at strengthening its financial position.
Medicenna's Stock Up 3.61% in One Day
Medicenna's market cap is now CA$34.6 million, reflecting optimism from investors driven by recent funding activities.
Bull case
Medicenna successfully completed a public offering that raised about $4.44 million by issuing nearly 8.88 million units. This new capital will help the company boost its research and development efforts, which could lead to important breakthroughs in its clinical trials.
Bear case
Despite the positive movement, the absence of immediate news or significant product developments could create volatility. Investors might be cautious about whether this upward trend can be sustained.
Recent Public Offering Boosts Investor Confidence
Medicenna recently wrapped up a public offering, raising around $4.44 million. This funding is expected to support the company's ongoing research and clinical trials, which are crucial for its future growth.
Market Response and Future Outlook
The positive response to Medicenna's stock reflects a broader trend of investor interest in biotech firms actively seeking funding to advance their projects. While the stock's rise is encouraging, investors should stay alert for the company's upcoming announcements and clinical trial results that could impact its stock performance.
Advertisement
